Recent Price Movement and Market Context
On 24 Nov 2025, Alpa Laboratories' share price touched Rs.78.01, the lowest level recorded in the past year. This decline comes despite a positive trend in the broader market, with the Sensex opening 88.12 points higher and trading at 85,421.92, a 0.22% gain. The Sensex is also approaching its 52-week high of 85,801.70, supported by mega-cap stocks and a bullish alignment of its 50-day and 200-day moving averages.
In contrast, Alpa Laboratories has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The stock has recorded a consecutive two-day decline, with a cumulative return of -1.73% over this period, underperforming its sector by 1.1% on the day.
Performance Over the Past Year
Over the last 12 months, Alpa Laboratories has delivered a return of -30.70%, a stark contrast to the Sensex's 7.97% gain during the same period. The stock's 52-week high was Rs.137.40, indicating a substantial reduction in market value. This performance places the company among the weaker performers within the Pharmaceuticals & Biotechnology sector.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Metrics Highlighting Challenges
Alpa Laboratories' financial data reveals several areas of concern. The company’s operating profit has shown a negative compound annual growth rate of approximately -206.03% over the last five years, indicating a contraction in core profitability. The most recent quarterly results for September 2025 show a profit after tax (PAT) of Rs.0.11 crore, reflecting a decline of 98.3% compared to the average of the previous four quarters.
The return on capital employed (ROCE) for the half-year period stands at 12.57%, which is among the lowest levels recorded. Additionally, the profit before depreciation, interest, and taxes (PBDIT) for the quarter was negative at Rs.-2.24 crore, signalling operational losses in the near term.
Risk Factors and Valuation Considerations
The stock is considered to carry elevated risk relative to its historical valuation levels. Over the past year, profits have declined by approximately 10.4%, compounding the negative return trend. Alpa Laboratories has also underperformed the BSE500 index over the last three years, one year, and three months, underscoring persistent challenges in both long-term and recent performance.
Despite these pressures, the company maintains a low average debt-to-equity ratio, effectively at zero, which may provide some balance sheet stability. The majority shareholding remains with promoters, indicating concentrated ownership.
Considering Alpa Laboratories ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Alpa Laboratories’ recent performance contrasts with the broader market’s upward trajectory. While the Sensex has gained 2.65% over the past three weeks, led by mega-cap stocks, Alpa Laboratories has continued to face downward pressure. The sector itself has experienced mixed results, with some companies benefiting from favourable market conditions and others encountering headwinds.
The stock’s current trading below all major moving averages further emphasises its subdued momentum relative to sector peers and the overall market.
Summary of Key Price and Performance Data
To summarise, Alpa Laboratories’ stock price has declined to Rs.78.01, a 52-week low, following a two-day losing streak with a cumulative fall of 1.73%. The stock’s one-year return is -30.70%, contrasting with the Sensex’s positive 7.97% return. Financial indicators reveal a contraction in profitability and negative quarterly earnings, while valuation metrics suggest elevated risk compared to historical norms.
These factors collectively illustrate the challenges faced by Alpa Laboratories in maintaining market value and financial stability amid a generally positive market environment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
